Future options with trastuzumab for primary systemic and adjuvant therapy-Reference-Cited by-同舟云学术

Future options with trastuzumab for primary systemic and adjuvant therapy

Published:2004-10 Issue: Volume:31 Page:51-57
ISSN:0093-7754
Container-title:Seminars in Oncology
language:en
Short-container-title:Seminars in Oncology

Author:

Baselga José,Gianni Luca,Geyer Charles,Perez Edith A.,Riva Alessandro,Jackisch Christian

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference39 articles.

1. Primary systemic therapy in operable breast cancer;Wolff;J Clin Oncol,2000

2. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer;Kauffman;J Clin Oncol,2003

3. Preoperative (neoadjuvant) chemotherapy in patients with breast cancer;Mamounas;Semin Oncol,2001

4. Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women;Smith;Breast Cancer Res Treat,2003

5. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer;Baum;Cancer,2003

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assembled Step Emulsification Device for Multiplex Droplet Digital Polymerase Chain Reaction;Analytical Chemistry;2019-01-04

2. Dual silencing of EGFR and HER2 enhances the sensitivity of gastric cancer cells to gefitinib;Molecular Carcinogenesis;2018-04-24

3. Large scale ex vivo expansion of clinical‑grade effector cells for adoptive immunotherapy;Experimental and Therapeutic Medicine;2017-09-29

4. Development and evaluation of a novel RT-qPCR based test for the quantification of HER2 gene expression in breast cancer;Gene;2017-03

5. Association Studies of Fcγ Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831;Cancer Immunology Research;2014-07-02